ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt
Release Date: 03/02/2016

ClinicalTrials.gov ID: NCT00462384

Study Identification

Unique Protocol ID:	ML20659
Brief Title:	A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Participants With Chronic Kidney Disease.
Official Title:	An Open-label, Multi-center Study to Demonstrate Correction of Anemia and to Assess the Maintenance of Hemoglobin Levels Using Subcutaneous Once Monthly Injections of Mircera in Pre-dialysis Patients With Chronic Kidney Disease
Secondary IDs:	

Study Status

Record Verification:	March 2016
Overall Status:	Terminated
Study Start:	February 2008
Primary Completion:	April 2011 [Actual]
Study Completion:	April 2011 [Actual]

Sponsor/Collaborators

Sponsor:	Hoffmann-La Roche
Responsible Party:	Sponsor
Collaborators:	

Oversight

FDA Regulated?:	No
IND/IDE Protocol?:	No

Review Board:	Approval Status: Approved Approval Number: 01/10/2007 Board Name: Ethics Committee Board Affiliation: Department of Medicine Phone: +358 9 471 71484 Email: anneli.keskinen@hus.fi
Data Monitoring?:	
Plan to Share Data?:	
Oversight Authorities:	Finland: National Agency of Medicines

Study Description

Brief Summary:	This single arm study will assess the efficacy and safety of subcutaneous Mircera for correction of anemia in participants with chronic kidney disease who are not on dialysis and are not treated with erythropoiesis-stimulating agents (ESA). Eligible participants will receive Mircera by monthly subcutaneous injections, dependent on body weight (with a starting dose of 1.2 micrograms/kilogram [mcg/kg]). The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
Detailed Description:	

Conditions

Conditions:	Anemia
Keywords:	

Study Design

Study Type:	Interventional
Primary Purpose:	Treatment
Study Phase:	Phase 3
Intervention Model:	Single Group Assignment
Number of Arms:	1
Masking:	Open Label
Allocation:	N/A
Endpoint Classification:	Safety/Efficacy Study
Enrollment:	39 [Actual]

Arms and Interventions

Arms	Assigned Interventions
Experimental: Methoxy Polyethylene Glycol-epoetin Beta Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose will be 1.2 micrograms per kilogram (mcg/kg) body weight. Thereafter, throughout the duration of study the dose adjustments will be performed depending on the hemoglobin value.	Drug: Methoxy Polyethylene Glycol-epoetin Beta Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose will be 1.2 mcg/kg body weight. Thereafter, throughout the duration of study the dose adjustments will be performed depending on the hemoglobin value. Other Names: • Mircera • RO0503821

Outcome Measures

[See Results Section.]

Eligibility

Minimum Age: 18 Years

Maximum Age:

Gender: Both

Accepts Healthy Volunteers?: No

Criteria: Inclusion Criteria:

- chronic kidney disease, stage 3 or 4;
- anemia (baseline hemoglobin between 9 and 11 grams per deciliter [g/dL]).

Exclusion Criteria:

- previous therapy with ESA within 12 weeks prior to screening;
- significant acute or chronic bleeding such as overt gastrointestinal bleeding;
- red blood cell transfusions within 8 weeks before screening;
- active malignant disease (except non-melanoma skin cancer).

Contacts/Locations

Study Officials: Clinical Trials
Study Director

Hoffmann-La Roche

Locations: Finland
HUS, Finland, 00029

Tampere, Finland, 33521

Turku, Finland, 20521

Kajaani, Finland, 87140

Jyväskylä, Finland, 40620

Kotka, Finland, 48210

Norway
Oslo, Norway, 0407

Trondheim, Norway, 7006

Lillehammer, Norway, 2629

Finland
Porvoo, Finland, 06151

Norway
Honefoss, Norway, 3504

Stavanger, Norway, 4011

Latvia
Riga, Latvia, 1002

Jurmala, Latvia, LV2015

Riga, Latvia, LV1038

Liepaja, Latvia, 3402

Valmiera, Latvia, 4201

Estonia
Tallinn, Estonia, 13419

Tallinn, Estonia, 10617

Tartu, Estonia, 51014

Latvia
Ventspils, Latvia, LV 3601

Finland
Joensuu, Finland, 80210

References

Citations:

Links:

Study Data/Documents:

Study Results

Participant Flow

Reporting Groups

	Description
Methoxy Polyethylene Glycol-epoetin Beta	Methoxy polyethylene glycol-epoetin beta was administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose was 1.2 micrograms per kilogram (mcg/kg) body weight. Thereafter, throughout the duration of study the dose adjustments were performed depending on the hemoglobin value.

Overall Study

	Methoxy Polyethylene Glycol-epoetin Beta
Started	39
Completed	30
Not Completed	9
Adverse Event	2
Death	2
Withdrawal by Subject	1
Unspecified	4

Baseline Characteristics

Analysis Population Description

Safety population: included all participants who were treated with at least one dose of the study medication.

Reporting Groups

	Description
Methoxy Polyethylene Glycol-epoetin Beta	Methoxy polyethylene glycol-epoetin beta was administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose was 1.2 mcg/kg body weight. Thereafter, throughout the duration of study the dose adjustments were performed depending on the hemoglobin value.

Baseline Measures

	Methoxy Polyethylene Glycol-epoetin Beta
Number of Participants	39
Age, Continuous [units: years] Mean (Standard Deviation)	61.6 (18.25)
Gender, Male/Female [units: participants]	
Female	28
Male	11

Outcome Measures

1. Primary Outcome Measure:

Measure Title	Mean Change in Hemoglobin Concentration Between Baseline and the Efficacy Evaluation Period (EEP)
Measure Description	The baseline hemoglobin was defined as the mean of the assessments recorded during the screening period (Weeks -2 and 0). EEP was the first 8 weeks (Weeks 29 to 36) following the 28 weeks dose titration period. EEP hemoglobin was defined as the mean of the assessments recorded during the EEP.
Time Frame	Baseline (Week -2 to 0) and EEP (Weeks 29 to 36)
Safety Issue?	No

Analysis Population Description

Intent to treat (ITT) population: included all participants who received at least one dose of methoxy polyethylene glycol-epoetin beta and for whom data for at least one study variable was available.

Reporting Groups

	Description
Methoxy Polyethylene Glycol-epoetin Beta	Methoxy polyethylene glycol-epoetin beta was administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose was 1.2 mcg/kg body weight. Thereafter, throughout the duration of study the dose adjustments were performed depending on the hemoglobin value.

Measured Values

	Methoxy Polyethylene Glycol-epoetin Beta
Number of Participants Analyzed	39
Mean Change in Hemoglobin Concentration Between Baseline and the Efficacy Evaluation Period (EEP) [units: grams per deciliter (g/dL)] Mean (Standard Deviation)	1.32 (0.88)

2. Secondary Outcome Measure:

Measure Title	Time to Achievement of Response
Measure Description	Time to achievement of response was the time (number of days) required to achieve hemoglobin levels within the range of 11.0 to 13.0 g/dL.
Time Frame	Baseline to Week 40
Safety Issue?	No

Analysis Population Description

ITT population

Reporting Groups

	Description
Methoxy Polyethylene Glycol-epoetin Beta	Methoxy polyethylene glycol-epoetin beta was administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose was 1.2 mcg/kg body weight. Thereafter, throughout the duration of study the dose adjustments were performed depending on the hemoglobin value.

Measured Values

	Methoxy Polyethylene Glycol-epoetin Beta
Number of Participants Analyzed	39
Time to Achievement of Response [units: days]	24.6 (20.53)

	Methoxy Polyethylene Glycol-epoetin Beta
Mean (Standard Deviation)	

3. Secondary Outcome Measure:

Measure Title	Percentage of Participants Maintaining Hemoglobin Concentration Within Hemoglobin Range 11.0 to 13.0 g/dL Throughout the EEP
Measure Description	EEP was the first 8 weeks (Weeks 29 to 36) following the 28 weeks dose titration period. The percentage of participants whose hemoglobin concentrations remained within the range of 11.0-13.0 g/dL at all assessments throughout the EEP is presented.
Time Frame	EEP (Weeks 29 to 36)
Safety Issue?	No

Analysis Population Description

ITT population

Reporting Groups

	Description
Methoxy Polyethylene Glycol-epoetin Beta	Methoxy polyethylene glycol-epoetin beta was administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose was 1.2 mcg/kg body weight. Thereafter, throughout the duration of study the dose adjustments were performed depending on the hemoglobin value.

Measured Values

	Methoxy Polyethylene Glycol-epoetin Beta
Number of Participants Analyzed	39
Percentage of Participants Maintaining Hemoglobin Concentration Within Hemoglobin Range 11.0 to 13.0 g/dL Throughout the EEP [units: percentage of participants]	53.9

4. Secondary Outcome Measure:

Measure Title	Percentage of Participants Maintaining Average Hemoglobin Concentration Within Hemoglobin Range 11.0 to 13.0 g/dL During the EEP

Measure Description	EEP was the first 8 weeks (Weeks 29 to 36) following the 28 weeks dose titration period. The percentage of participants whose average hemoglobin concentration was within the range of 11.0-13.0 g/dL during the EEP is presented.
Time Frame	EEP (Weeks 29 to 36)
Safety Issue?	No

Analysis Population Description
ITT population

Reporting Groups

	Description
Methoxy Polyethylene Glycol-epoetin Beta	Methoxy polyethylene glycol-epoetin beta was administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose was 1.2 mcg/kg body weight. Thereafter, throughout the duration of study the dose adjustments were performed depending on the hemoglobin value.

Measured Values

	Methoxy Polyethylene Glycol-epoetin Beta
Number of Participants Analyzed	39
Percentage of Participants Maintaining Average Hemoglobin Concentration Within Hemoglobin Range 11.0 to 13.0 g/dL During the EEP [units: percentage of participants]	66.7

5. Secondary Outcome Measure:

Measure Title	Time Spent in Hemoglobin Range of 11.0 to 13.0 g/dL During the EEP
Measure Description	EEP was the first 8 weeks (Weeks 29 to 36) following the 28 weeks dose titration period.
Time Frame	EEP (Weeks 29 to 36)
Safety Issue?	No

Analysis Population Description
ITT population

Reporting Groups

	Description
Methoxy Polyethylene Glycol-epoetin Beta	Methoxy polyethylene glycol-epoetin beta was administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose was 1.2 mcg/kg body weight. Thereafter, throughout the duration of study the dose adjustments were performed depending on the hemoglobin value.

Measured Values

	Methoxy Polyethylene Glycol-epoetin Beta
Number of Participants Analyzed	39
Time Spent in Hemoglobin Range of 11.0 to 13.0 g/dL During the EEP [units: days] Mean (Standard Deviation)	42.5 (13.96)

Reported Adverse Events

Time Frame	Baseline up to Week 40
Additional Description	Safety population

Reporting Groups

	Description
Methoxy Polyethylene Glycol-epoetin Beta	Methoxy polyethylene glycol-epoetin beta was administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose was 1.2 mcg/kg body weight. Thereafter, throughout the duration of study the dose adjustments were performed depending on the hemoglobin value.

Serious Adverse Events

	Methoxy Polyethylene Glycol-epoetin Beta
	Affected/At Risk (%)
Total	11/39 (28.21%)
Cardiac disorders	
Angina pectoris [A] *	1/39 (2.56%)
Arteriosclerosis coronary artery [A] *	1/39 (2.56%)

	Methoxy Polyethylene Glycol-epoetin Beta
	Affected/At Risk (%)
Atrial fibrillation [A] *	1/39 (2.56%)
Infections and infestations	
Bronchitis [A] *	1/39 (2.56%)
Otitis media chronic [A] *	1/39 (2.56%)
Pneumonia [A] *	1/39 (2.56%)
Postoperative wound infection [A] *	1/39 (2.56%)
Metabolism and nutrition disorders	
Iron deficiency [A] *	1/39 (2.56%)
Musculoskeletal and connective tissue disorders	
Back pain [A] *	1/39 (2.56%)
Pregnancy, puerperium and perinatal conditions	
Intra-uterine death [A] *	1/39 (2.56%)
Renal and urinary disorders	
Azotaemia [A] *	1/39 (2.56%)
Reproductive system and breast disorders	
Postmenopausal haemorrhage [A] *	1/39 (2.56%)
Skin and subcutaneous tissue disorders	
Skin ulcer [A] *	1/39 (2.56%)
Surgical and medical procedures	
Foot amputation [A] *	1/39 (2.56%)
Vascular disorders	
Peripheral ischaemia [A] *	1/39 (2.56%)

* Indicates events were collected by non-systematic methods.

A Term from vocabulary, MedDRA 15.1

Other Adverse Events

Frequency Threshold Above Which Other Adverse Events are Reported: 5%

	Methoxy Polyethylene Glycol-epoetin Beta
	Affected/At Risk (%)
Total	11/39 (28.21%)
Infections and infestations	
Urinary tract infection [A] *	4/39 (10.26%)
Psychiatric disorders	
Insomnia [A] *	2/39 (5.13%)
Renal and urinary disorders	
Urine odour abnormal [A] *	2/39 (5.13%)
Vascular disorders	
Hypertension [A] *	5/39 (12.82%)

* Indicates events were collected by non-systematic methods.

A Term from vocabulary, MedDRA 15.1

Limitations and Caveats

This study was terminated early due to strategic decision unrelated to safety or efficacy.

More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.

Results Point of Contact:

Name/Official Title: Medical Communications

Organization: Hoffmann-La Roche
Phone: 800-821-8590
Email: genentech@druginfo.com